sglt2 with glp 1 Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients type 2 diabetes mellitus (T2DM) | Cardiovascular Diabetology Do We Need to Withhold

A formal human pharmacokinetic half-life has not been published

Jia et al., 2016), breast cancer cell lines (Teplyuk et al., 2008)

This formulation consists of high-purity peptides , manufactured under controlled conditions and supplied as LPS-free peptides

Test characteristics Species Human Sample types Serum and EDTA plasma Sample volume 25 L Assay range 0.9 - 940 pmol/L (2.8 - 2940 pg/mL) Detection limit 0.65 pmol/L Incubation 2h + 15 min Detection method Chemiluminescence specificity The following cross-reactions have been tested: GLP-1 (1-36) amide 88% GLP-1 (7-36) amide 93% GLP-1 (9-36) amide 100% GLP-1 (1-37) Not detected GLP-1 (7-37) Not detected Glucagon Not detected GIP Not detected GLP-2 Not detected Oxyntomodulin Not detected Glicentin Not detected Miniglucagon Not detected MPGF Not detected Liraglutide Not detected Exenatide Not detected Lixisenatide Not detected Dulaglutide 0.07% directions for use Certificate of Analysis directions for use Certificate of Analysis SAFETY DATA SHEET technical notes For technical notes specific to Mercodia Total GLP-1 ELISA see: TN34-0154 Sample collection and handling for Mercodia Total GLP-1 ELISA (10-1278-01) references Stinson, S